April 18 (Reuters) - The U.S. Food and Drug Administration approved the extended use of Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
(Reporting by Christy Santhosh and Gnaneshwar Rajan in Bengaluru; Editing by Alison Williams)
((Gnaneshwar.Rajan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.